Skip to main content

Table 1 Detail characteristics of studies included

From: Safety and efficacy of interleukin-6-receptor inhibitors in the treatment of neuromyelitis optica spectrum disorders: a meta-analysis

Authors Year IL-6 inhibitors used Type of study Regions/Countries Sample Size Follow-up Sex (Female/Male) Mean age/Range Mean disease Duration AQP-4 ab positive Dose of drugs used Add on drugs/Previously used drugs
Ayzenberg 2013 Tocilizumab Retrospective study Germany 3 18 months 3/0 39 years (26–40 years) 8.2 years (2.5–9.4 years) 3 (100%) 6 mg/kg every 6 weeks in patients 1 and 2 and every 4 weeks in patient 3 interferon beta-1a and 1b (n = 2), glatiramer acetate (n = 1), azathioprine (n = 1), and mitoxantrone hydrochloride (n = 1). Rituximab
Araki 2014 Tocilizumab Pilot study Japan 7 12 months 6/1 12–60 years NA 7 (100%) A monthly dose (8 mg/kg) oral prednisolone, (PSL) and immunosuppressants, including azathioprine
Ringelstein 2015 Tocilizumab Retrospective Study Germany 8 30.9 + −15.9 months 8/0 29.4 years (25–49 years) 7.9 + −7.7 8 (100%) 4 of 8 patients at a reduced dosage of 6 mg/kg in 4-week to 6-week intervals, for the other 4 patients dosage of 8 mg/kg at regular 4-week intervals. immunosuppressant medications, including interferon beta-1b (n = 3), interferon beta-1a (n = 2), azathioprine (n = 2), mitoxantrone (n = 2), mycophenolate mofetil (n = 1), natalizumab (n = 1), glatiramer acetate (n = 1), alemtuzumab (n = 1), and monthly intravenous corticosteroids
Guarnizo 2018 Tocilizumab Retrospective Study Spain 5 NA 3/2 50 + −5.3 years 2.3 years 2 (40%) 8 mg/kg body weight every 4 weeks Immunosuppressants like rituximab(n = 5), cyclophosphamide(n = 2) and azathioprine (1)
Lotan 2019 Tocilizumab Retrospective study USA 12 31.8 + − 18.8 months 11/1 46.9 + − 14.5 (26–68) years 6.8 + − 4.6 years 7 (58.3%) subcutaneous dose of 162 mg every 1–2 weeks Corticosteroids, mycophenolate mofetil, intravenous immunoglobulins
Rigal 2020 Tocilizumab Retrospective study France 4 23 months 4/0 35.75 years (20–63 years) 7.85 (2–15 years) 4 (100%) 8 mg/kg for monthly intravenous cycles and 162 mg weekly for subcutaneous injections MMF, Rituximab, Azathioprine
Zhang 2020 Tocilizumab Randomized Controlled Trial 6 centers in China 59 60 weeks 55/4 48.1 + −13.4 years 6 + −2.9 years 50 (85%) intravenous tocilizumab 8 mg/kg every 4 weeks. Azathioprine (AZA) in placebo group
Yamamura 2019 Satralizumab Randomized Controlled Trial 34 centers in 11 countries 41 NA 37/4 40.8 + −16.1 years (13–73 years) NA 27 (66%) dose of 120 mg administered subcutaneously at weeks 0, 2, and 4 and every 4 weeks AZA, mycophenolate mofetil, glucocorticoids in both groups.
Traboulsee 2020 Satralizumab Randomized Controlled Trial 44 centers in 13 countries 63 NA 46/17 45.3 ± 12.0 (21–70 years) NA 41 (65%) 120 mg subcutaneously at weeks 0, 2, 4, and every 4 weeks None